Estrogen receptors

Lung adenocarcinoma is the main type of lung cancer in women. Our previous findings have evidenced that 25-hydroxycholesterol (25-HC) promotes migration and invasion of lung adenocarcinoma cells (LAC), during which LXR as a 25-HC receptor plays an important role.

14p vishanshan 27-06-2024 1 1   Download

Despite numerous studies on racial/ethnic disparities among patients with breast cancer, there is a paucity of literature evaluating racial/ethnic differences in 21-gene recurrence score (RS) and survival diferences stratifed by RS risk categories. We thus performed an observational cohort study to examine racial/ethnic disparities in the context of RS.

8p vishanshan 27-06-2024 1 1   Download

Breast cancer (BC) is one of the major causes of death worldwide. It is the most common cause of death before the age of 70 years. The incidence and mortality of BC are rapidly increasing, posing great challenges to the health system and economy of every nation.

11p vishanshan 27-06-2024 1 1   Download

This research designeded to: 1. Analyze the efficacy and safety of Palbociclib treatment in HR-positive and HER2-negative (HR+/HER2-) metastatic breast cancer(MBC) patients. 2. Establish and validate a nomogram model for predicting the progression-free survival (PFS) rates of 6 months, 12 months, and 18 months in HR+/HER2- MBC patients after receiving Palbociclib plus endocrine therapy (ET).

13p vishanshan 27-06-2024 1 1   Download

Guidance on tailored precision therapy with consideration of genomic mutations was possible for some patients with information provided by F1CDx. Clinicians should consider using F1CDx at turning points in the course of the disease.

9p vishanshan 27-06-2024 2 1   Download

Breast cancer (BC) is the most commonly diagnosed cancer in women. Treatment approaches that differ between estrogen-positive (ER+) and triple-negative BC cells (TNBCs) and may subsequently affect cancer biomarkers, such as H19 and telomerase, are an emanating delight in BC research.

21p vishanshan 27-06-2024 1 1   Download

Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resistance, however, remain unknown.

14p vibransone 28-03-2024 5 2   Download

Estrogen receptor (ER) activity is critical for the development and progression of the majority of breast cancers. It is known that ER is differentially bound to DNA leading to transcriptomic and phenotypic changes in different breast cancer models.

11p vioraclene 31-03-2024 5 2   Download

Phenotypic changes during cancer progression are associated with alterations in gene expression, which can be exploited to build molecular signatures for tumor stage identification and prognosis. However, it is not yet known whether the relative abundance of transcript isoforms may be informative for clinical stage and survival.

14p vioraclene 31-03-2024 4 2   Download

Normal cell BRCA1 epimutations have been associated with increased risk of triple-negative breast cancer (TNBC). However, the fraction of TNBCs that may have BRCA1 epimutations as their underlying cause is unknown. Neither are the time of occurrence and the potential inheritance patterns of BRCA1 epimutations established.

15p vicwell 29-02-2024 5 1   Download

P-glycoprotein (P-gp), a member of the ATP Binding Cassette B1 subfamily (ABCB1), confers resistance to clinically relevant anticancer drugs and targeted chemotherapeutics. However, paradoxically P-glycoprotein overexpressing drug resistant cells are “collaterally sensitive” to non-toxic drugs that stimulate its ATPase activity.

14p vileonardodavinci 23-12-2023 4 2   Download

Estrogen receptor-positive and progesterone receptor-negative (ER+/PR-) breast cancer comprise a special type. More than 10% breast cancer patients belonged to ER+/PR-. In this study, we identified the clinical and genetic characteristics of ER+/PR- breast cancer patients in China. Distinct PR statuses indicated different biological processes of ER+breast cancer and survival outcomes. Future treatment strategies may need to be tailored for ER+/PR- patients.

11p vileonardodavinci 23-12-2023 6 2   Download

Public health systems in both industrialized and undeveloped countries continue to struggle with the worldwide problem of breast cancer. In sub-Saharan African countries, notably Ethiopia, it is the form of cancer that strikes women the most commonly. Despite the extreme difficulties, the causes of mortality in Ethiopia have not yet been identified. In addition, little study has been done in this area.

13p vileonardodavinci 23-12-2023 3 2   Download

The objective of this study was to determine the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor (HER2), Ki67 and their correlation with other prognostic factors in invasive ductal carcinoma of breast.

5p vispacex 13-11-2023 6 2   Download

Breast cancer patients of American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) Group 2 were all HER2-negative according to the 2018 guideline, not HER2-positive as defined in the 2013 guideline.

13p vischultz 20-10-2023 6 1   Download

Rearranged during transfection (RET) tyrosine kinase signaling has been previously implicated in endocrine resistant breast cancer, however the mechanism by which this signaling cascade promotes resistance is currently not well described.

14p vischultz 20-10-2023 3 1   Download

Triple negative BCa (TNBC) is defined by a lack of expression of estrogen (ERα), progesterone (PgR) receptors and human epidermal growth factor receptor 2 (HER2) as assessed by protein expression and/or gene amplification.

12p vischultz 20-10-2023 3 1   Download

Progesterone receptor (PR)-negative tumors have been shown to have worse prognosis and were underrepresented in recent trials on patients with estrogen receptor (ER)-positive breast cancer. The role of PR-nega‑ tive status in the context of 21-gene recurrence score (RS) and nodal staging remains unclear.

8p vischultz 20-10-2023 2 1   Download

Heterogeneous tumor cells are thought to be a significant factor in the failure of endocrine therapy in estrogen receptor-positive (ER+) cancers. Culturing patient-derived breast cancer cells (PDBCCs) provides an invaluable tool in pre-clinical and translational research for the heterogeneity of cancer cells.

13p vioracle 29-09-2023 8 2   Download

Radiotherapy (RT) following breast-conserving surgery (BCS) is mainly used to decrease the rate of ipsilateral breast tumor recurrence (IBTR) in women with breast ductal carcinoma in situ (DCIS). Recent studies have demonstrated that low-dose tamoxifen significantly reduces IBTR in breast DCIS.

10p vioracle 29-09-2023 5 2   Download